Increasing Prevalence of BPH with the Expanding Ageing Population has Propelled the Growth of the Benign Prostatic Hyperplasia Devices Market in the APAC Region!

BPH is a common condition among aging men, and Asia Pacific has a large and rapidly aging population, particularly in countries like China, India, Japan, and South Korea. As per the World Bank data, in 2022, around 87,652,339 and 46,443,962 number of population ages 65 and above of males in China and India respectively. This demographic trend has been a major driver of market growth in the region. The improving healthcare infrastructure and rising healthcare expenditure in many Asian countries have led to increased awareness about BPH and its treatment options. As a result, more men are seeking medical advice and intervention for BPH-related issues that drive the demand for BPH devices.

Access sample report (including graphs, charts, and figures): https://univdatos.com/get-a-free-sample-form-php/?product_id=42445

Further,the APAC Benign Prostatic Hyperplasia Devices Market is expected to grow at a strong CAGR of 6.8% during the forecast period (2022-2030). APAC is anticipated to emerge as the fastest-growing benign prostatic hyperplasia devices market primarily owing to the rising prevalence of benign prostatic hyperplasia. In China, the estimated prevalence of BPH is 36.6%, and it increases markedly from 2.9% in men aged 40–49 years to 69.2% in men aged 80 years or older, as stated by the Asian Journal of Andrology, in 2023.

APAC Benign prostatic hyperplasia devices Market Revenue (2020-2030)- USD Mn

By device type, the market is segmented into transurethral resection of the prostate (TURP), transurethral needle ablation (TUNA), transurethral incision of the prostate (TUIP), transurethral microwave thermotherapy (TUMT), laser therapy, electrosurgery, and others. Amongst these, the electrosurgery segment is expected to grow with a significant CAGR during the forecast period (2023-2030). The electrosurgery segment’s ability to offer effective, versatile, and minimally invasive procedures for BPH treatment, along with continuous technological advancements, has significantly contributed to driving the growth of benign prostatic hyperplasia devices. For instance, in June 2023, Olympus Corporation launched the ESG-410 Electrosurgical Generator, the market availability of its newest electrosurgical generator for use in the treatment of bladder cancer and enlarged prostate.

Based on the technology, the market is segmented into radiofrequency ablation devices, resectoscopes, urology lasers, prostatic stents, and implants. Among these, urology lasers are expected to grow with a significant CAGR during the forecast period (2023-2030). The use of urology lasers such as holmium lasers and GreenLight lasers, in benign prostatic hyperplasia device treatment offers few advantages over conventional surgeries, including less blood loss, shorter recovery time, and reduced chance of complications. As per Boston Scientific Corporation, above one million men worldwide have been treated with GreenLight Laser Therapy for BPH in 2023.

For a detailed analysis of the Global Benign prostatic hyperplasia devices Market browse through – https://univdatos.com/report/benign-prostatic-hyperplasia-devices-market/

Global Benign Prostatic Hyperplasia Devices Market Segmentation

Market Insight, by Device Type

• Transurethral Resection of the Prostate (TURP)
• Transurethral Needle Ablation (TUNA)
• Transurethral Incision of Prostate (TUIP)
• Transurethral Microwave Thermotherapy (TUMT)
• Laser Therapy
• Electrosurgery
• Others

Market Insights, by Technology

• Radiofrequency Ablation Devices
• Resectoscopes
• Urology Lasers
• Prostatic Stents
• Implants

Market Insights, by End-Users

• Hospitals
• Ambulatory Surgical Centers
• Physician Offices
• Others

Market Insight, by Region

• North America
  • U.S.
  • Canada
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • India
  • South Korea
  • Rest of APAC
• Rest of the World

Top Company Profiles

• Olympus Corporation
• Boston Scientific Corporation
• Butterfly
• SRS Medical
• Teleflex Incorporated
• Urotronic
• Zenflow, Inc.
• ProArc
• Medeon Biodesign, Inc
• Urologix, LLC